[HTML][HTML] Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
J Kuball, K de Boer, E Wagner, M Wattad… - Cancer immunology …, 2011 - Springer
T cells with specificity for antigens derived from Wilms Tumor gene (WT1), Proteinase3 (Pr3),
and mucin1 (MUC1) have been demonstrated to lyse acute myeloid leukemia (AML) blasts …
and mucin1 (MUC1) have been demonstrated to lyse acute myeloid leukemia (AML) blasts …
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid …
E Olavarria, S Siddique, MJ Griffiths… - Blood, The Journal …, 2007 - ashpublications.org
Disease relapse is a major cause of treatment failure after reduced-intensity allografts and
while donor lymphocyte infusions (DLIs) can be effective salvage therapy they are …
while donor lymphocyte infusions (DLIs) can be effective salvage therapy they are …
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
MH Cohen, G Williams, JR Johnson, J Duan… - Clinical cancer …, 2002 - AACR
Purpose: Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-
Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis. Imatinib …
Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis. Imatinib …
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 …
KJ Aichberger, M Mayerhofer, MT Krauth, H Skvara… - Blood, 2005 - ashpublications.org
Antiapoptotic members of the bcl-2 family have recently been implicated in the pathogenesis
of chronic myeloid leukemia (CML), a hematopoietic neoplasm associated with the …
of chronic myeloid leukemia (CML), a hematopoietic neoplasm associated with the …
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous …
JR Johnson, P Bross, M Cohen, M Rothmann… - Clinical Cancer …, 2003 - AACR
Purpose: The purpose is to describe the Food and Drug Administration (FDA) review and
approval of imatinib (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of …
approval of imatinib (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of …